Skip to main content

Peer Review reports

From: The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma

Original Submission
23 May 2015 Submitted Original manuscript
Author responded Author comments
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Author responded Author comments
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
11 May 2016 Editorially accepted
17 May 2016 Article published 10.1186/s12878-016-0053-9

You can find further information about peer review here.

Back to article page